First Human Clinical Study of HIV Vaccine Vacc-C5 Approved to Begin
May 29, 2012 11:22 ET
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - May 29, 2012) - Bionor Pharma ASA (OSLO: BIONOR)
News Summary
Open, clinical study, dose escalating, phase I/II, with Bionor...
Bionor Pharma's Shareholders Voted Industry Experts Steen Kroyer, Jerry Zeldis and Benedicte Fossum to Its Board of Directors at Annual General Meeting
May 11, 2012 08:52 ET
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - May 11, 2012) - Bionor Pharma ASA (OSLO: BIONOR) announced today unanimously shareholder approval for new and re-elected Board members to the Board of Directors, and...
Successful Immunization and Safety Documented in Nasal Administration Study of the HIV Vaccine Vacc-4x Together With Endocine
May 10, 2012 06:47 ET
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - May 10, 2012) - Bionor Pharma (OSLO: BIONOR)
News Summary
Vaccine related immune responses found in HIV patients given Vacc-4x...
With Final Review of Phase IIb Viral Load Data Completed, Researchers Confirm Statistically Significant Reduction of HIV Viral Load on Vacc-4x Compared to Placebo
February 15, 2012 08:00 ET
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - Feb 15, 2012) - Bionor Pharma (OSLO: BIONOR)
News Summary
Final review of phase IIb data confirms statistically significant 64%...
With Final Documentation Submitted for International Patent Applications, Bionor Sees Promise of Two Core Platform Technologies
January 23, 2012 08:00 ET
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - Jan 23, 2012) -
News Summary
Bionor Pharma ASA has previously submitted two international patent applications for the Company's...
Researchers Study Nasal Administration of Bionor Pharma's Therapeutic HIV Vaccine Vacc-4x Combined With Eurocine Vaccines' Endocine(TM) in Fully Enrolled Trial; New Treatment Option Would Offer Easier Treatment Access for HIV Patients Globally
January 04, 2012 08:00 ET
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - Jan 4, 2012) -
News Summary
Bionor Pharma's Vacc-4x is an investigational therapeutic HIV vaccine that has already shown in a...
Bionor Pharma's Universal Influenza Vaccine, Vacc-Flu, Targets Regions Shared by All Influenza A Strains; Reduces Serious Flu Symptoms by 25 Percent Over Standard Flu Vaccine in Animal Study
November 22, 2011 08:00 ET
|
Bionor Pharma
ARLINGTON, VA--(Marketwire - Nov 22, 2011) -
Summary of Findings
Bionor's Vacc-Flu could be "Universal," meaning that it could work on seasonal flu and also on...
Hemispherx Biopharma, Inc. to Host Conference Call on Chronic Fatigue Syndrome Progress Thursday, October 27, 2011
October 24, 2011 10:22 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Oct. 24, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex: HEB) (the "Company"), has scheduled a conference call and audio webcast on Thursday, October 27, 2011 at 2:00...
Results From Phase IIB Placebo Controlled Study of Bionor Pharma's Vacc-4x Show Excellent Safety Profile, Statistically Significant Viral Load Reduction in Patients With HIV Who Suspend Antiretroviral Therapy
September 14, 2011 02:30 ET
|
BionorPharma
BANGKOK, THAILAND--(Marketwire - Sep 14, 2011) - Results from the furthest advanced study of a therapeutic vaccine candidate to treat people living with HIV/AIDS were announced at a news conference...
Bionor Pharma ASA Announces Exploratory Study of Its Lead Therapeutic HIV-Vaccine Candidate Vacc-4x in Combination With Leading Cancer Drug
August 25, 2011 08:00 ET
|
BionorPharma
OSLO, NORWAY--(Marketwire - Aug 25, 2011) - Bionor Pharma ASA (OSLO: BIONOR) announces plans to conduct an exploratory clinical study using Bionor Pharma's therapeutic HIV-vaccine candidate,...